Evaluating Carbon Ion Radiotherapy for Liver Cancer
Author Information
Author(s): Stephanie E. Combs, Daniel Habermehl, Tom Ganten, Jan Schmidt, Lutz Edler, Iris Burkholder, Oliver Jäkel, Thomas Haberer, Jürgen Debus
Primary Institution: University Hospital of Heidelberg
Hypothesis
The study aims to determine the optimal dose of carbon ion radiotherapy for patients with advanced hepatocellular carcinoma (HCC).
Conclusion
The PROMETHEUS-01 trial will assess the safety and efficacy of carbon ion radiotherapy in treating advanced HCC.
Supporting Evidence
- Carbon ion therapy has shown promising results in previous studies for treating liver cancer.
- The study aims to find the maximum tolerated dose of carbon ion therapy for safety.
- Patients will be monitored for toxicity and treatment response over a period of time.
Takeaway
This study is testing a new type of radiation therapy for liver cancer to see how much can be given safely and if it helps patients.
Methodology
The study is a single-center Phase I dose escalation trial evaluating carbon ion radiotherapy in patients with advanced HCC.
Limitations
The study is limited to a single center and may not be generalizable to all patient populations.
Participant Demographics
Patients must be adults with histologically confirmed HCC and liver-confined disease.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website